CA
BCAX

Clearstead Advisors’s Bicara Therapeutics BCAX Stock Holding History

Clearstead Advisors’s Portfolio BCAX Stock Details BCAX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$149 Buy
+5
New +$112 ﹤0.01% 3272

Other funds holding BCAX

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
RTM
Red Tree Management Redwood City, California $147M AUM 202.18% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $5B AUM 58.56% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Clearstead Advisors's BCAX Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Bicara Therapeutics (BCAX) in Q2 2026: 5 shares worth $149. The stake represents ﹤0.01% of the portfolio and ranks #3272 among its holdings.

172 funds tracked by Wall St. Rank hold BCAX as of Q2 2026.

  • Clearstead Advisors held 5 shares of Bicara Therapeutics worth $149 as of Q2 2026.
  • Bicara Therapeutics was a new Clearstead Advisors position in Q2 2026.
  • Bicara Therapeutics made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3272 holding.
  • 172 funds tracked by Wall St. Rank held Bicara Therapeutics as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.